| Literature DB >> 29463607 |
Fu-Han Gong1, Wen-Lin Cheng1, Haiping Wang1, Maomao Gao2, Juan-Juan Qin2, Yan Zhang1, Xia Li2, Xueyong Zhu1, Hao Xia3, Zhi-Gang She4.
Abstract
Atherosclerosis is considered to be a chronic inflammatory disease that can lead to severe clinically important cardiovascular events. miR-150 is a small noncoding RNA that significantly enhances inflammatory responses by upregulating endothelial cell proliferation and migration, as well as intravascular environmental homeostasis. However, the exact role of miR-150 in atherosclerosis remains unknown. Here, we investigated the effect of miR-150 deficiency on atherosclerosis development. Using double-knockout (miR-150-/- and ApoE-/-) mice, we measured atherosclerotic lesion size and stability. Meanwhile, we conducted in vivo bone marrow transplantation to identify cellular-level components of the inflammatory response. Compared with mice deficient only in ApoE, the double-knockout mice had significantly smaller atherosclerotic lesions and displayed an attenuated inflammatory response. Moreover, miR-150 ablation promoted plaque stabilization via increases in smooth muscle cell and collagen content and decreased macrophage infiltration and lipid accumulation. The in vitro experiments indicated that an inflammatory response with miR-150 deficiency in atherosclerosis results directly from upregulated expression of the cytoskeletal protein, PDZ and LIM domain 1 (PDLIM1), in macrophages. More importantly, the decreases in phosphorylated p65 expression and inflammatory cytokine secretion induced by miR-150 ablation were reversed by PDLIM1 knockdown. These findings suggest that miR-150 is a promising target for the management of atherosclerosis.Entities:
Keywords: PDZ and LIM domain 1; inflammation; microRNA-150
Mesh:
Substances:
Year: 2018 PMID: 29463607 PMCID: PMC5880493 DOI: 10.1194/jlr.M082651
Source DB: PubMed Journal: J Lipid Res ISSN: 0022-2275 Impact factor: 5.922